The Multiple Sclerosis Center of Atlanta (MSCA) has announced it is now administering
TYSABRI® (natalizumab), the drug recently re-released by the U.S. Food and Drug Administration
(FDA). TYSABRI, manufactured by Biogen Idec and Elan Corp., treats relapsing forms of multiple
sclerosis (MS) to reduce the frequency of clinical relapses. TYSABRI is the first humanized
monoclonal antibody approved for the treatment of MS.
Free Forum Hosting
Important Announcement
First 